The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Disease duration and the integrity of the nigrostriatal system in Parkinson’s disease
Open accessAbstract
The pace of nigrostriatal degeneration, both with regards to striatal denervation and loss of melanin and tyrosine hydroxylase-positive neurons, is poorly understood especially early in the Parkinson's disease process. This study investigated the extent of nigrostriatal degeneration in patients with Parkinson's disease at different disease durations from time of diagnosis. Brains of patients with Parkinson's disease (n=28) with post-diagnostic intervals of 1-27 years and normal elderly control subjects (n=9) were examined. Sections of the post-commissural putamen and substantia nigra pars compacta were processed for tyrosine hydroxylase and dopamine transporter immunohistochemistry. The post-commissural putamen was selected due to tissue availability and the fact that dopamine loss in this region is associated with motor disability in Parkinson's disease. Quantitative assessments of putaminal dopaminergic fibre density and stereological estimates of the number of melanin-containing and tyrosine hydroxylase-immunoreactive neurons in the substantia nigra pars compacta (both in total and in subregions) were performed by blinded investigators in cases where suitable material was available (n=17). Dopaminergic markers in the dorsal putamen showed a modest loss at 1 year after diagnosis in the single case available for study. There was variable (moderate to marked) loss, at 3 years. At 4 years post-diagnosis and thereafter, there was virtually complete loss of staining in the dorsal putamen with only an occasional abnormal dopaminergic fibre detected. In the substantia nigra pars compacta, there was a 50-90% loss of tyrosine hydroxylase-positive neurons from the earliest time points studied with only marginal additional loss thereafter. There was only a ∼10% loss of melanized neurons in the one case evaluated 1 year post-diagnosis, and variable (30 to 60%) loss during the first several years post-diagnosis with more gradual and subtle loss in the second decade. At all time points, there were more melanin-containing than tyrosine hydroxylase-positive cells. Loss of dopaminergic markers in the dorsal putamen occurs rapidly and is virtually complete by 4 years post-diagnosis. Loss of melanized nigral neurons lags behind the loss of dopamine markers. These findings have important implications for understanding the nature of Parkinson's disease neurodegeneration and for studies of putative neuroprotective/restorative therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
AGEING AND PARKINSON'S DISEASE: SUBSTANTIA NIGRA REGIONAL SELECTIVITY
FEARNLEY, J. M., & LEES, A. J. (1991) · Brain · doi:10.1093/brain/114.5.2283 · Cited by 3,529
The efficiency of systematic sampling in stereology and its prediction*
Gundersen, H. J. G., & Jensen, E. B. (1987) · Journal of Microscopy · doi:10.1111/j.1365-2818.1987.tb02837.x · Cited by 3,520
Bernheimer, H., Birkmayer, W., Hornykiewicz, O., Jellinger, K., & Seitelberger, F. (1973) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(73)90175-5 · Cited by 2,651
Wiklund, R. A., & Rosenbaum, S. H. (1997) · New England Journal of Medicine · doi:10.1056/nejm199710163371606 · Cited by 2,149
Lang, A. E., & Lozano, A. M. (1998) · New England Journal of Medicine · doi:10.1056/nejm199810083391506 · Cited by 1,994
Uneven Pattern of Dopamine Loss in the Striatum of Patients with Idiopathic Parkinson's Disease
Kish, S. J., Shannak, K., & Hornykiewicz, O. (1988) · New England Journal of Medicine · doi:10.1056/nejm198804073181402 · Cited by 1,953
Ehringer, H., & Hornykiewicz, O. (1960) · Klinische Wochenschrift · doi:10.1007/bf01485901 · Cited by 1,867
The substantia nigra of the human brain
Damier, P., Hirsch, E. C., Agid, Y., & Graybiel, A. M. (1999) · Brain · doi:10.1093/brain/122.8.1437 · Cited by 1,756
Lewy body–like pathology in long-term embryonic nigral transplants in Parkinson's disease
Kordower, J. H., Chu, Y., Hauser, R. A., Freeman, T. B., & Olanow, C. W. (2008) · Nature Medicine · doi:10.1038/nm1747 · Cited by 1,722
Self-citationMelanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease
Hirsch, E., Graybiel, A. M., & Agid, Y. A. (1988) · Nature · doi:10.1038/334345a0 · Cited by 1,301
Cited by
Kalia, L. V., & Lang, A. E. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61393-3 · Cited by 6,184
Poewe, W., Seppi, K., Tanner, C. M., Halliday, G. M., Brundin, P., Volkmann, J., Schrag, A.-E., & Lang, A. E. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.13 · Cited by 5,415
Self-citationRole of neuroinflammation in neurodegeneration development
Zhang, W., Xiao, D., Mao, Q., & Xia, H. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01486-5 · Cited by 1,668
Selective neuronal vulnerability in Parkinson disease
Surmeier, D. J., Obeso, J. A., & Halliday, G. M. (2017) · Nature Reviews Neuroscience · doi:10.1038/nrn.2016.178 · Cited by 1,116
Self-citationvon Bartheld, C. S., Bahney, J., & Herculano‐Houzel, S. (2016) · Journal of Comparative Neurology · doi:10.1002/cne.24040 · Cited by 1,063
Calabresi, P., Mechelli, A., Natale, G., Volpicelli-Daley, L., Di Lazzaro, G., & Ghiglieri, V. (2023) · Cell Death & Disease · doi:10.1038/s41419-023-05672-9 · Cited by 817
The Parkinson's progression markers initiative (PPMI) – establishing a PD biomarker cohort
Marek, K., Chowdhury, S., Siderowf, A., Lasch, S., Coffey, C. S., Caspell‐Garcia, C., Simuni, T., Jennings, D., Tanner, C. M., Trojanowski, J. Q., et al. (2018) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.644 · Cited by 671
The Role of Astrocyte Dysfunction in Parkinson’s Disease Pathogenesis
Booth, H. D. E., Hirst, W. D., & Wade-Martins, R. (2017) · Trends in Neurosciences · doi:10.1016/j.tins.2017.04.001 · Cited by 633
Recasens, A., Dehay, B., Bové, J., Carballo‐Carbajal, I., Dovero, S., Pérez‐Villalba, A., Fernagut, P., Blesa, J., Parent, A., Perier, C., et al. (2014) · Annals of Neurology · doi:10.1002/ana.24066 · Cited by 632
Parkinson's disease: Mechanisms, translational models and management strategies
Raza, C., Anjum, R., & Shakeel, N. U. A. (2019) · Life Sciences · doi:10.1016/j.lfs.2019.03.057 · Cited by 603
Smajić, S., Prada-Medina, C. A., Landoulsi, Z., Ghelfi, J., Delcambre, S., Dietrich, C., Jarazo, J., Henck, J., Balachandran, S., Pachchek, S., et al. (2022) · Brain · doi:10.1093/brain/awab446 · Cited by 590
Savelieff, M. G., Nam, G., Kang, J., Lee, H. J., Lee, M., & Lim, M. H. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00138 · Cited by 581
Disruption of mitochondrial complex I induces progressive parkinsonism
González-Rodríguez, P., Zampese, E., Stout, K. A., Guzman, J. N., Ilijic, E., Yang, B., Tkatch, T., Stavarache, M. A., Wokosin, D. L., Gao, L., et al. (2021) · Nature · doi:10.1038/s41586-021-04059-0 · Cited by 546
Intestinal dysbiosis and lowered serum lipopolysaccharide-binding protein in Parkinson's disease
Hasegawa, S., Goto, S., Tsuji, H., Okuno, T., Asahara, T., Nomoto, K., Shibata, A., Fujisawa, Y., Minato, T., Okamoto, A., et al. (2015) · PLOS ONE · doi:10.1371/journal.pone.0142164 · Cited by 523
Parkinson’s Disease: Etiology, Neuropathology, and Pathogenesis
John van Geest Centre for Brain Repair, D. O. C. N., Kouli, A., Torsney, K. M., Department of Medicine for the Elderly, C. U. H. N. F. T., Clinical Gerontology Unit, D. O. P. H. A. P. C., Kuan, W.-L., & John van Geest Centre for Brain Repair, D. O. C. N. (2018) · Parkinson’s Disease: Pathogenesis and Clinical Aspects · doi:10.15586/codonpublications.parkinsonsdisease.2018.ch1 · Cited by 507
Oxidative stress and regulated cell death in Parkinson’s disease
Dionísio, P. A., Amaral, J. D., & Rodrigues, C. M. P. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101263 · Cited by 424
Gut-seeded α-synuclein fibrils promote gut dysfunction and brain pathology specifically in aged mice
Challis, C., Hori, A., Sampson, T. R., Yoo, B. B., Challis, R. C., Hamilton, A. M., Mazmanian, S. K., Volpicelli-Daley, L. A., & Gradinaru, V. (2020) · Nature Neuroscience · doi:10.1038/s41593-020-0589-7 · Cited by 405
Genetics and Pathogenesis of Parkinson's Syndrome
Ye, H., Robak, L. A., Yu, M., Cykowski, M., & Shulman, J. M. (2023) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-031521-034145 · Cited by 416
On Cell Loss and Selective Vulnerability of Neuronal Populations in Parkinson's Disease
Giguère, N., Burke Nanni, S., & Trudeau, L.-E. (2018) · Frontiers in Neurology · doi:10.3389/fneur.2018.00455 · Cited by 413
Schapira, A. H. V., Olanow, C. W., Greenamyre, J. T., & Bezard, E. (2014) · The Lancet · doi:10.1016/s0140-6736(14)61010-2 · Cited by 392
Self-citationα-Synuclein-specific T cell reactivity is associated with preclinical and early Parkinson’s disease
Lindestam Arlehamn, C. S., Dhanwani, R., Pham, J., Kuan, R., Frazier, A., Rezende Dutra, J., Phillips, E., Mallal, S., Roederer, M., Marder, K. S., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15626-w · Cited by 386
Lang, A. E., & Espay, A. J. (2018) · Movement Disorders · doi:10.1002/mds.27360 · Cited by 370
Calabrese, V., Santoro, A., Monti, D., Crupi, R., Di Paola, R., Latteri, S., Cuzzocrea, S., Zappia, M., Giordano, J., Calabrese, E. J., et al. (2018) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2017.10.379 · Cited by 356
Modeling Parkinson’s disease in midbrain-like organoids
Smits, L. M., Reinhardt, L., Reinhardt, P., Glatza, M., Monzel, A. S., Stanslowsky, N., Rosato-Siri, M. D., Zanon, A., Antony, P. M., Bellmann, J., et al. (2019) · npj Parkinson's Disease · doi:10.1038/s41531-019-0078-4 · Cited by 356
Ferroptosis and cell death mechanisms in Parkinson's disease
Guiney, S. J., Adlard, P. A., Bush, A. I., Finkelstein, D. I., & Ayton, S. (2017) · Neurochemistry International · doi:10.1016/j.neuint.2017.01.004 · Cited by 338
Johansson, M. E., Cameron, I. G. M., Van der Kolk, N. M., de Vries, N. M., Klimars, E., Toni, I., Bloem, B. R., & Helmich, R. C. (2022) · Annals of Neurology · doi:10.1002/ana.26291 · Cited by 300
Polinski, N. K., Volpicelli-Daley, L. A., Sortwell, C. E., Luk, K. C., Cremades, N., Gottler, L. M., Froula, J., Duffy, M. F., Lee, V. M. Y., Martinez, T. N., et al. (2018) · Journal of Parkinson’s Disease · doi:10.3233/jpd-171248 · Cited by 288
Warren Olanow, C., Bartus, R. T., Baumann, T. L., Factor, S., Boulis, N., Stacy, M., Turner, D. A., Marks, W., Larson, P., Starr, P. A., et al. (2015) · Annals of Neurology · doi:10.1002/ana.24436 · Cited by 287
Self-citationIron and dopamine: a toxic couple
Hare, D. J., & Double, K. L. (2016) · Brain · doi:10.1093/brain/aww022 · Cited by 283
Whone, A., Luz, M., Boca, M., Woolley, M., Mooney, L., Dharia, S., Broadfoot, J., Cronin, D., Schroers, C., Barua, N. U., et al. (2019) · Brain · doi:10.1093/brain/awz023 · Cited by 282
Morbelli, S., Esposito, G., Arbizu, J., Barthel, H., Boellaard, R., Bohnen, N. I., Brooks, D. J., Darcourt, J., Dickson, J. C., Douglas, D., et al. (2020) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-020-04817-8 · Cited by 273
Retrograde Axonal Degeneration in Parkinson Disease
Tagliaferro, P., & Burke, R. E. (2016) · Journal of Parkinson’s Disease · doi:10.3233/jpd-150769 · Cited by 272
The ongoing pursuit of neuroprotective therapies in Parkinson disease
Athauda, D., & Foltynie, T. (2015) · Nature Reviews Neurology · doi:10.1038/nrneurol.2014.226 · Cited by 269
Dementia with Lewy bodies and Parkinson’s disease-dementia: current concepts and controversies
Jellinger, K. A. (2018) · Journal of Neural Transmission · doi:10.1007/s00702-017-1821-9 · Cited by 264
Initiation and propagation of α-synuclein aggregation in the nervous system
Hijaz, B. A., & Volpicelli-Daley, L. A. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-020-00368-6 · Cited by 262
Blesa, J., Trigo-Damas, I., Dileone, M., del Rey, N. L.-G., Hernandez, L. F., & Obeso, J. A. (2017) · Experimental Neurology · doi:10.1016/j.expneurol.2017.10.002 · Cited by 256
Parkinson’s disease as a result of aging
Rodriguez, M., Rodriguez‐Sabate, C., Morales, I., Sanchez, A., & Sabate, M. (2015) · Aging Cell · doi:10.1111/acel.12312 · Cited by 214
Lewy body-like alpha-synuclein inclusions trigger reactive microgliosis prior to nigral degeneration
Duffy, M. F., Collier, T. J., Patterson, J. R., Kemp, C. J., Luk, K. C., Tansey, M. G., Paumier, K. L., Kanaan, N. M., Fischer, D. L., Polinski, N. K., et al. (2018) · Journal of Neuroinflammation · doi:10.1186/s12974-018-1171-z · Cited by 197
Christine, C. W., Bankiewicz, K. S., Van Laar, A. D., Richardson, R. M., Ravina, B., Kells, A. P., Boot, B., Martin, A. J., Nutt, J., Thompson, M. E., et al. (2019) · Annals of Neurology · doi:10.1002/ana.25450 · Cited by 167
Mead, B. P., Kim, N., Miller, G. W., Hodges, D., Mastorakos, P., Klibanov, A. L., Mandell, J. W., Hirsh, J., Suk, J. S., Hanes, J., et al. (2017) · Nano Letters · doi:10.1021/acs.nanolett.7b00616 · Cited by 151
In vivo imaging of neuromelanin in Parkinson’s disease using18F-AV-1451 PET
Hansen, A. K., Knudsen, K., Lillethorup, T. P., Landau, A. M., Parbo, P., Fedorova, T., Audrain, H., Bender, D., Østergaard, K., Brooks, D. J., et al. (2016) · Brain · doi:10.1093/brain/aww098 · Cited by 128
In vivo gastric detection of α-synuclein inclusions in Parkinson's disease
Sánchez‐Ferro, Á., Rábano, A., Catalán, M. J., Rodríguez‐Valcárcel, F. C., Díez, S. F., Herreros‐Rodríguez, J., García‐Cobos, E., Álvarez‐Santullano, M. M., López‐Manzanares, L., Mosqueira, A. J., et al. (2015) · Movement Disorders · doi:10.1002/mds.25988 · Cited by 123
Molecular Mechanisms Underlying Synaptic and Axon Degeneration in Parkinson’s Disease
Gcwensa, N. Z., Russell, D. L., Cowell, R. M., & Volpicelli-Daley, L. A. (2021) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2021.626128 · Cited by 110
Volta, M., Beccano-Kelly, D. A., Paschall, S. A., Cataldi, S., MacIsaac, S. E., Kuhlmann, N., Kadgien, C. A., Tatarnikov, I., Fox, J., Khinda, J., et al. (2017) · eLife · doi:10.7554/elife.28377 · Cited by 108
Bartus, R. T., & Johnson, E. M. (2017) · Neurobiology of Disease · doi:10.1016/j.nbd.2016.03.027 · Cited by 97
Self-citationFeng, S.-T., Wang, Z.-Z., Yuan, Y.-H., Sun, H.-M., Chen, N.-H., & Zhang, Y. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104336 · Cited by 96
Cognitive flexibility in neurological disorders: Cognitive components and event-related potentials
Lange, F., Seer, C., & Kopp, B. (2017) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2017.09.011 · Cited by 84
Christine, C. W., Richardson, R. M., Van Laar, A. D., Thompson, M. E., Fine, E. M., Khwaja, O. S., Li, C., Liang, G. S., Meier, A., Roberts, E. W., et al. (2022) · Neurology · doi:10.1212/wnl.0000000000012952 · Cited by 89
Wu, J., Kung, J., Dong, J., Chang, L., Xie, C., Habib, A., Hawes, S., Yang, N., Chen, V., Liu, Z., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.06.095 · Cited by 87
Chu, Y., Bartus, R. T., Manfredsson, F. P., Olanow, C. W., & Kordower, J. H. (2020) · Brain · doi:10.1093/brain/awaa020 · Cited by 88
Self-citationTorra, A., Parent, A., Cuadros, T., Rodríguez-Galván, B., Ruiz-Bronchal, E., Ballabio, A., Bortolozzi, A., Vila, M., & Bové, J. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.02.022 · Cited by 88
Mind matters: placebo enhances reward learning in Parkinson's disease
Schmidt, L., Braun, E. K., Wager, T. D., & Shohamy, D. (2014) · Nature Neuroscience · doi:10.1038/nn.3842 · Cited by 84
Salvatore, M. F., Calipari, E. S., & Jones, S. R. (2016) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.6b00064 · Cited by 72
Padel, T., Özen, I., Boix, J., Barbariga, M., Gaceb, A., Roth, M., & Paul, G. (2016) · Neurobiology of Disease · doi:10.1016/j.nbd.2016.06.002 · Cited by 70
Chotibut, T., Meadows, S., Kasanga, E. A., McInnis, T., Cantu, M. A., Bishop, C., & Salvatore, M. F. (2017) · Movement Disorders · doi:10.1002/mds.27077 · Cited by 56
Onset pattern of nigrostriatal denervation in early Parkinson’s disease
Pineda-Pardo, J. A., Sánchez-Ferro, Á., Monje, M. H. G., Pavese, N., & Obeso, J. A. (2022) · Brain · doi:10.1093/brain/awab378 · Cited by 51
Sgobio, C., Wu, J., Zheng, W., Chen, X., Pan, J., Salinas, A. G., Davis, M. I., Lovinger, D. M., & Cai, H. (2017) · Scientific Reports · doi:10.1038/s41598-017-05598-1 · Cited by 47
Stephenson, D., Hill, D., Cedarbaum, J. M., Tome, M., Vamvakas, S., Romero, K., Conrado, D. J., Dexter, D. T., Seibyl, J., Jennings, D., et al. (2019) · Journal of Parkinson’s Disease · doi:10.3233/jpd-191648 · Cited by 46
Qiao, C.-M., Quan, W., Zhou, Y., Niu, G.-Y., Hong, H., Wu, J., Zhao, L.-P., Li, T., Cui, C., Zhao, W.-J., et al. (2023) · Molecular Neurobiology · doi:10.1007/s12035-023-03392-x · Cited by 45
Liu, D., Guo, J.-J., Su, J.-H., Svanbergsson, A., Yuan, L., Haikal, C., Li, W., Gouras, G., & Li, J.-Y. (2021) · Translational Neurodegeneration · doi:10.1186/s40035-021-00242-5 · Cited by 32
Parkinson’s Disease: Can Targeting Inflammation Be an Effective Neuroprotective Strategy?
Gundersen, V. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.580311 · Cited by 33
Retromer in Synaptic Function and Pathology
Brodin, L., & Shupliakov, O. (2018) · Frontiers in Synaptic Neuroscience · doi:10.3389/fnsyn.2018.00037 · Cited by 29
Back to the origins: Human brain organoids to investigate neurodegeneration
Faravelli, I., Costamagna, G., Tamanini, S., & Corti, S. (2020) · Brain Research · doi:10.1016/j.brainres.2019.146561 · Cited by 25
Flinkman, D., Hong, Y., Gnjatovic, J., Deshpande, P., Ortutay, Z., Peltonen, S., Kaasinen, V., James, P., & Coffey, E. (2023) · npj Parkinson's Disease · doi:10.1038/s41531-023-00460-w · Cited by 20
PTEN-Induced Putative Kinase 1 Dysfunction Accelerates Synucleinopathy
Nguyen, T. T., Kim, Y. J., Lai, T. T., Nguyen, P. T., Koh, Y. H., Nguyen, L. T. N., Ma, H.-I., & Kim, Y. E. (2022) · Journal of Parkinson's Disease · doi:10.3233/jpd-213065 · Cited by 8
Metadata
- Authors
- Kordower, J. H., Olanow, C. W., Dodiya, H. B., Chu, Y., Beach, T. G., Adler, C. H., Halliday, G. M., & Bartus, R. T.
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2013-07-23
- Volume
- 136
- Issue
- 8
- Pages
- 2419-2431
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- OpenAlex
- W1978793506
- Cited by
- 1,286
- References
- 33
- FWCI
- 36.47
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.